Fluorescein Sodium
CAS 518-47-8
Fluorescein Sodium (CAS 518-47-8) is a Phase 4 pharmaceutical compound with 4 bioactivity targets and 31 adverse event associations.
Compound Identity
Matched identifiers and naming fields for the pharmaceutical compound record.
Clinical Development Phase
Highest clinical development phase rendered from the matched compound identifier rows.
Cross-Reference to Cosmetics
Same-CAS ingredient record found in the cosmetics vertical.
Bioactivity & Target Interactions
Target-level activity records with assay counts, activity type, and measured value where present.
| Target | Activity | Value | Assays | Organism |
|---|---|---|---|---|
| Cytochrome P450 2C19 Enzyme |
IC50 | 6.042 | - | Homo sapiens |
| Protein arginine N-methyltransferase 1 Enzyme |
IC50 | 4.12 | - | Homo sapiens |
| Solute carrier family 22 member 6 Transporter |
Ki | 5.53 | - | Mus musculus |
| Solute carrier family 22 member 20 Transporter |
Ki | 4 | - | Mus musculus |
Adverse Event Associations
DrugCentral / FAERS disproportionality signal rows matched to this compound.
| Reaction PT | Drug AE | LLR | MedDRA |
|---|---|---|---|
| Anaphylactic shock | 76 | 301.351 | 10002199 |
| Anaphylactic reaction | 40 | 96.024 | 10002198 |
| Chest discomfort | 34 | 60.643 | 10008469 |
| Haemangioma congenital | 11 | 59.753 | 10018818 |
| Urticaria | 37 | 57.162 | 10046735 |
| Pruritus | 49 | 53.458 | 10037087 |
| Histamine level increased | 7 | 52.556 | 10060051 |
| Cold sweat | 17 | 51.699 | 10009866 |
Association rows are source-linked signal records, not incidence rates or clinical causality claims.
Drug Names / RxNorm
Normalized drug-name vocabulary rows, RxCUIs, and source abbreviations.
| Name | RxCUI | Type | Source |
|---|---|---|---|
| FLUORESCEIN SODIUM | 57789 | SU | MTHSPL |
| fluorescein sodium | 57789 | SU | MTHSPL |
| fluorescein sodium | 57789 | PIN | RXNORM |
Frequently Asked Questions
Short answers generated only from the same visible source-linked rows on this page.
What is Fluorescein Sodium used for in pharmaceutical contexts?
Fluorescein Sodium (CAS 518-47-8) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.
What are the known adverse events for Fluorescein Sodium?
Fluorescein Sodium has 31 DrugCentral/FAERS adverse event associations. Rendered reaction terms include Anaphylactic shock, Anaphylactic reaction, Chest discomfort, Haemangioma congenital, Urticaria. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.
Is Fluorescein Sodium also used in cosmetics?
Yes. The ingredients table has a same-CAS cosmetic profile for CI 45350 with EU status "permitted".
What clinical phase is Fluorescein Sodium in?
Fluorescein Sodium is rendered with ChEMBL max phase 4 (approved).
What bioactivity targets are documented for Fluorescein Sodium?
Fluorescein Sodium has 4 bioactivity rows in this page query. Rendered target entries include Cytochrome P450 2C19, Protein arginine N-methyltransferase 1, Solute carrier family 22 member 6, Solute carrier family 22 member 20.